A novel orally available asthma drug candidate that reduces smooth muscle constriction and inflammation by targeting GABA(A) receptors in the lung

We describe lead compound MIDD0301 for the oral treatment of asthma based on previously developed positive allosteric α(5)β(3)γ(2) selective GABA(A) receptor (GABA(A)R) ligands. MIDD0301 relaxed airway smooth muscle at single micromolar concentrations as demonstrated with ex vivo guinea pig tracheal...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Pharm
Main Authors: Forkuo, Gloria S., Nieman, Amanda N., Kodali, Revathi, Zahn, Nicolas M., Li, Guanguan, Rashid Roni, M. S., Stephen, Michael Rajesh, Harris, Ted W., Jahan, Rajwana, Guthrie, Margaret L., Yu, Olivia B., Fisher, Janet L., Yocum, Gene T., Emala, Charles W., Steeber, Douglas A., Stafford, Douglas C., Cook, James M., Arnold, Leggy A.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5954213/
https://ncbi.nlm.nih.gov/pubmed/29578347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.7b01013
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki